ArticleInflammopharmacology2025
Gallic acid enhances memory, learning and reduces neuroinflammation in a rat model of scopolamine-induced cholinergic dysfunction.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Investigating the molecular mechanisms underlying the neuroprotective potential of ellagic acid in scopolamine-induced learning and memory dysfunction.Research in pharmaceutical sciences · 2026Article
- Mitochondrial Fusion and Fission in Age-Related Cardio-Cerebral Diseases: Mechanisms and Interventions.Aging cell · 2026Review
- Behavioral and Biochemical Evaluation of a Curcumin-Loaded Nano-Liposomal Formulation in a Scopolamine-Induced Mouse Model of Cognitive Impairment.Biomolecules & therapeutics · 2026Article
- Protective Effects of Gallic Acid on Oxidative and Inflammatory Markers in the Hippocampus and Prefrontal Cortex of a Ketamine-Induced Schizophrenia-like Model.Brain sciences · 2026Article
- Investigating the protective effect of zinc oxide-gallic acid nanoparticles against depression like behavior and memory impairment in animals treated with D-galactose.Scientific reports · 2026Article
- Grapefruit By-Products as a Sustainable Source of Bioaccessible Polyphenols with In Vitro Neuroprotective Potential.International journal of molecular sciences · 2026Article
- Anxiolytic and cognitive effects of dietary phenolics in zebrafish: rosmarinic acid, gallic acid, and 3-hydroxytyrosol.Frontiers in pharmacology · 2026Article
- Downregulation of Neuralized1 in the Hippocampal CA1 Through Reducing CPEB3 Ubiquitination Mediates Synaptic Plasticity Impairment and Cognitive Deficits in Neuropathic Pain.Neuroscience bulletin · 2025Article
- Research on the Protective Effects and Mechanisms of Gallic Acid Against Cognitive Impairment Induced by Chronic Sleep Deprivation.Nutrients · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Gallic acid (GA), a potent polyphenol antioxidant, has demonstrated beneficial effects on the nervous system. This study aimed to investigate the neuroprotective potential of GA on learning and memory in a rat model of scopolamine-induced cholinergic dysfunction. Additionally, the roles of oxidative stress and neuroinflammation were examined. Rats were divided into six groups: Control, scopolamine (2 mg/kg/day), scopolamine plus 25, 50, or 100 mg/kg of GA, and scopolamine plus 2 mg/kg of donepezil (DN, administered once daily). Behavioral performance was evaluated using the Morris Water Maze (MWM) and Passive Avoidance Test. Biochemical parameters were assessed to determine oxidative stress, and gene expression analyses were conducted to explore neuroinflammation in the hippocampus. The behavioral tests revealed that both GA and DN treatments improved the rats' performance in the MWM, as evidenced by their ability to locate the platform and spend more time in the target area. Additionally, GA administration increased the latency of entering the dark compartment and extended the time spent in the light compartment while reducing the frequency of dark compartment entries in the Passive Avoidance Test. Furthermore, GA exhibited antioxidant, anti-acetylcholinesterase, and anti-inflammatory effects, as indicated by the modulation of malondialdehyde levels, thiol content, superoxide dismutase activity, acetylcholinesterase activity, and the expression of inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, and IL-6. In conclusion, this study provides evidence for the potential therapeutic benefits of GA in Alzheimer's disease, highlighting its ability to enhance memory function and mitigate oxidative stress, acetylcholinesterase activity, and inflammation.
Indexed as
Identifiers
40090981What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.